No Data
CStone Pharmaceuticals Grants Commercial Rights of Tumor Drug for MENA Region to UAE Firm
Cornerstone Pharmaceuticals-B (02616.HK) has reached a global strategy cooperation with Pharmalink regarding Sugrilimab in the Middle East and Africa.
Goldenway November 21st | Base Stone Pharmaceuticals-B (02616.HK) announced that the company has reached a commercial strategic cooperation with Pharmalink Store- L.L.C - O.P.C ("Pharmalink"). Pharmalink is a well-known pharmaceutical company based in the United Arab Emirates. According to the licensing and commercialization agreement, Pharmalink will obtain the commercialization of Shuglie monoclonal antibody in the Middle East and North Africa region, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Algeria, and Tunisia.
Express News | CStone Pharmaceuticals - CStone & Pharmalink Enter Into Strategic Partnership for Sugemalimab in Middle East, North Africa Region & South Africa
CStone Pharmaceuticals Showcases Breakthrough in Cancer Therapy
Founder Pharmaceuticals Group -B (02616.HK) announced the preclinical research data of CS2009 at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Gelonghui November 11th | Founder Pharmaceuticals-B (02616.HK) announced that the company released the pipeline 2.0 heavyweight product CS2009's preclinical data at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. Key highlights: • CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. • Preclinical data shows that CS2009 has significantly better anti-tumor activity than potential competitors. • CS2009 is expected to
Cornerstone Pharmaceuticals Group - B (02616) will announce the latest clinical data of CS5001 for lymphoma at the 66th American Society of Hematology (ASH) Annual Meeting.
Cornerstone Pharmaceuticals-B (02616) announced that the company will present at the 66th American Society of Hematology (ASH) Annual Meeting...
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
No Data
No Data
